arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

UroGen Pharma Ltd.

URGN Health Care Biotechnology: Pharmaceutical Preparations
$44.09
Today
as of Sep 4, 16:55 ET
Last 30 days +7.85% Jul 28 → Sep 04
$37.28 $40.77 $44.27 $47.76 $51.25 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$44.54
High
$45.09
Low
$43.51
Volume
$340,239
Avg Vol
$901,781
Mkt Cap
$2.4B
P/E (TTM)
—
Beta
—
52w High
$50.81
52w Low
$15.86
Div Yield
—
Shares Out
$49M

Recent Press Releases & News last 60 days · 25 items

Sep 4 · 12:00 PR GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2 · 12:00 PR GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
Aug 24 · 21:07 MT Newswires
Urogen Pharma Insider Sold Shares Worth $2,854,853, According to a Recent SEC Filing
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$16
$51
81% of range
Avg surprise (last 3)
-7.6%
Avg reaction (last 2)
+8.7%
100% positive
Latest IV / EM
91%
EM ±14.3% · $44 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.05$-0.91$-0.76$-0.61$-0.47 Actual $-0.92Est $-0.83Actual $-1.05Est $-0.82Actual $-0.47Est $-0.56 Mar/2025Jun/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-50M$-18M$13M$45M$76M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed May 6, 2026Mar/2026 $-0.47 $-0.56 +16.1% +48.9% +10.2% earnings
Thu Aug 7, 2025Jun/2025 $-1.05 $-0.82 -28.1% — — earnings
Mon May 12, 2025Mar/2025 $-0.92 $-0.83 -10.8% — +7.3% earnings

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$72M$51M—$27M$24M$20M—$25M
Cost of revenue$7M$4M—$3M$4M$2M—$2M
Gross profit$66M$47M—$24M$21M$18M—$23M
Operating income$111,000$-20M—$-27M$-41M$-37M—$-18M
Net income$-14M$-24M—$-33M$-50M$-44M—$-24M
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$79M$110M$111M$90M$93M$104M$172M$125M
Inventory$25M$21M$16M$8M$7M$8M$9M$8M
Total current assets$235M$237M$186M$169M$197M$237M$276M$295M
Total assets$253M$254M$200M$185M$209M$248M$286M$302M
Long-term debt$189M$190M$122M$122M$123M$122M$122M$122M
Total liabilities$385M$378M$306M$300M$302M$294M$295M$276M
Total equity$-132M$-124M$-105M$-115M$-93M$-46M$-9M$26M

Implied volatility — last 90 days

64%129%194%258%323% Jun 08 — IV 138% · EM ±18.3%Jun 09 — IV 139% · EM ±17.4%Jun 10 — IV 108% · EM ±12.8%Jun 11 — IV 160% · EM ±17.6%Jun 12 — IV 109% · EM ±11.2%Jun 15 — IV 171% · EM ±12.4%Jun 16 — IV 254% · EM ±15.0%Jun 17 — IV 310% · EM ±13.0%Jun 19 — IV 91% · EM ±20.1%Jun 22 — IV 88% · EM ±18.4%Jun 23 — IV 80% · EM ±16.4%Jun 24 — IV 65% · EM ±13.0%Jun 25 — IV 83% · EM ±16.3%Jun 26 — IV 93% · EM ±17.9%Jun 29 — IV 86% · EM ±15.3%Jun 30 — IV 95% · EM ±16.4%Jul 01 — IV 93% · EM ±15.6%Jul 02 — IV 91% · EM ±14.7%Jul 03 — IV 94% · EM ±14.7%Jul 06 — IV 107% · EM ±14.8%Jul 07 — IV 89% · EM ±11.8%Jul 08 — IV 94% · EM ±11.7%Jul 09 — IV 91% · EM ±10.8%Jul 10 — IV 110% · EM ±12.2%Jul 13 — IV 131% · EM ±10.9%Jul 14 — IV 120% · EM ±8.7%Jul 15 — IV 217% · EM ±12.8%Jul 16 — IV 323% · EM ±13.5%Jul 20 — IV 89% · EM ±20.9%Jul 21 — IV 101% · EM ±23.4%Jul 22 — IV 94% · EM ±21.5%Jul 23 — IV 83% · EM ±18.7%Jul 24 — IV 92% · EM ±20.4%Jul 27 — IV 88% · EM ±18.4%Jul 28 — IV 91% · EM ±18.5%Jul 29 — IV 109% · EM ±21.8%Jul 30 — IV 91% · EM ±17.8%Jul 31 — IV 102% · EM ±19.6%Aug 03 — IV 119% · EM ±21.1%Aug 04 — IV 108% · EM ±18.7%Aug 05 — IV 85% · EM ±14.2%Aug 06 — IV 79% · EM ±12.7%Aug 07 — IV 76% · EM ±11.9%Aug 10 — IV 92% · EM ±12.8%Aug 11 — IV 93% · EM ±12.3%Aug 12 — IV 77% · EM ±9.6%Aug 13 — IV 97% · EM ±11.4%Aug 14 — IV 97% · EM ±10.7%Aug 17 — IV 112% · EM ±9.4%Aug 18 — IV 95% · EM ±6.8%Aug 19 — IV 105% · EM ±6.2%Aug 20 — IV 132% · EM ±5.5%Aug 24 — IV 79% · EM ±16.5%Aug 25 — IV 70% · EM ±14.3%Aug 26 — IV 65% · EM ±13.0%Aug 27 — IV 80% · EM ±15.7%Aug 28 — IV 78% · EM ±14.8%Aug 31 — IV 77% · EM ±13.6%Sep 01 — IV 84% · EM ±14.4%Sep 02 — IV 80% · EM ±13.4%Sep 03 — IV 69% · EM ±11.1%Sep 04 — IV 91% · EM ±14.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in